CN112142845A - 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途 - Google Patents

纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途 Download PDF

Info

Publication number
CN112142845A
CN112142845A CN202010898460.6A CN202010898460A CN112142845A CN 112142845 A CN112142845 A CN 112142845A CN 202010898460 A CN202010898460 A CN 202010898460A CN 112142845 A CN112142845 A CN 112142845A
Authority
CN
China
Prior art keywords
seq
pai
region
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010898460.6A
Other languages
English (en)
Chinese (zh)
Inventor
A·普里茨克尔
P·格拉耶
A·拉克
M·马蒂厄
C·R·摩根
N·包林
B·波里尔
C·达弗
F·迪非厄
H·李
D·科米诺斯
P·雅尼亚克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of CN112142845A publication Critical patent/CN112142845A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
CN202010898460.6A 2013-08-13 2014-08-13 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途 Pending CN112142845A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361865451P 2013-08-13 2013-08-13
US61/865,451 2013-08-13
EP14305757.8 2014-05-22
EP14305757 2014-05-22
CN201480055157.2A CN105705520B (zh) 2013-08-13 2014-08-13 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480055157.2A Division CN105705520B (zh) 2013-08-13 2014-08-13 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途

Publications (1)

Publication Number Publication Date
CN112142845A true CN112142845A (zh) 2020-12-29

Family

ID=56194112

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010898460.6A Pending CN112142845A (zh) 2013-08-13 2014-08-13 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
CN201480055157.2A Active CN105705520B (zh) 2013-08-13 2014-08-13 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480055157.2A Active CN105705520B (zh) 2013-08-13 2014-08-13 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途

Country Status (17)

Country Link
US (4) US9845363B2 (cg-RX-API-DMAC7.html)
JP (5) JP6696899B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160035077A (cg-RX-API-DMAC7.html)
CN (2) CN112142845A (cg-RX-API-DMAC7.html)
BR (1) BR112016002753A2 (cg-RX-API-DMAC7.html)
CL (1) CL2016000324A1 (cg-RX-API-DMAC7.html)
CR (2) CR20190319A (cg-RX-API-DMAC7.html)
DO (1) DOP2016000042A (cg-RX-API-DMAC7.html)
EA (1) EA033403B1 (cg-RX-API-DMAC7.html)
ES (1) ES2770507T3 (cg-RX-API-DMAC7.html)
HK (1) HK1221725A1 (cg-RX-API-DMAC7.html)
MX (2) MX2016001851A (cg-RX-API-DMAC7.html)
PE (1) PE20160244A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016500239A1 (cg-RX-API-DMAC7.html)
SG (1) SG10201710013RA (cg-RX-API-DMAC7.html)
TN (1) TN2016000048A1 (cg-RX-API-DMAC7.html)
UA (1) UA118267C2 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA118267C2 (uk) * 2013-08-13 2018-12-26 Санофі Антитіло до інгібітора активатора плазміногену 1 (раі-1) та його застосування
WO2017101870A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防或治疗糖尿病性视网膜病变的方法
CN108778320A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗心血管病的新方法
DK3395354T3 (da) 2015-12-18 2024-06-03 Talengen Int Ltd Plasminogen til anvendelse i behandling af diabetisk nefropati
ES2982294T3 (es) 2015-12-18 2024-10-15 Talengen Int Ltd Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus
WO2018107690A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法
CN108210910A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗系统性硬化症的药物及其用途
CN110114079A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗肥胖症的方法和药物
US11311607B2 (en) * 2016-12-15 2022-04-26 Talengen International Limited Method for making glucagon and insulin restore normal balance
CN108210900A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肥胖症的药物及其用途
WO2018107697A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肺纤维化的方法
JP7182793B2 (ja) * 2016-12-15 2022-12-05 タレンゲン インターナショナル リミテッド 病理学的腎組織損傷を予防及び治療するための方法
JP7335609B2 (ja) 2017-06-19 2023-08-30 タレンゲン インターナショナル リミテッド Ｇｌｐ－１／ｇｌｐ－１ｒを調節制御する方法および薬剤
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
PE20200486A1 (es) * 2017-08-03 2020-03-03 Alector Llc Anticuerpos anti-cd33 y metodos para utilizarlos
CA3176021A1 (en) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use
US20220340665A1 (en) 2019-09-30 2022-10-27 Renascience Inc. Inhibitor against expression of immune checkpoint molecule
KR20220093327A (ko) * 2019-10-28 2022-07-05 모나쉬 유니버시티 플라스미노겐에 결합하기 위한 항체
TWI884192B (zh) * 2019-12-05 2025-05-21 美商西健公司 抗αＶβ６抗體及抗體-藥物結合物
CN115605219A (zh) * 2020-02-11 2023-01-13 泰伦基国际有限公司（Hk） 一种治疗病毒性肺炎的方法和药物
CN111072780B (zh) * 2020-03-24 2020-06-23 深圳汉盛汇融再生医学科技有限公司 白血病干细胞抑制剂及其在治疗慢性粒细胞白血病中的应用
AR122480A1 (es) * 2020-05-21 2022-09-14 Cadila Healthcare Ltd VARIANTE DE LA Fc Y PREPARACIÓN DE LA MISMA
CN114605550B (zh) * 2020-12-08 2023-09-22 东莞市朋志生物科技有限公司 抗ca19-9的抗体、其应用和检测ca19-9的试剂盒
CN114686441B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 一种能分泌tPAI-C单克隆抗体的杂交瘤细胞株及其应用
CN114686442B (zh) * 2020-12-31 2023-11-07 广州万孚生物技术股份有限公司 一种杂交瘤细胞株及其应用
CN115873120B (zh) * 2022-09-08 2025-10-21 厦门英博迈生物科技有限公司 一种纤溶酶α2纤溶酶抑制物复合物抗体及应用
WO2025032553A1 (en) * 2023-08-10 2025-02-13 Cochlear Limited Methods of treating inner ear fibrosis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422245A (en) * 1985-07-12 1995-06-06 Fonden Til Fremme Af Eksperimental Cancerforskning Plasminogen activator inhibitor monoclonal antibodies, hybridomas, monoclonal antibody production and use of the antibodies for assay of the inhibitors
US20020086838A1 (en) * 2000-01-14 2002-07-04 Tanox, Inc. Use of antagonists of plasminogen activator inhibitor-1 (PAI-1) for the treatment of asthma and chronic obstructive pulmonary disease
US20030217371A1 (en) * 2002-02-19 2003-11-20 Vanderbilt University Therapeutic methods employing PAI-1 inhibitors and transgenic non-human animal for screening candidate PAI-1 inhibitors
US20090081239A1 (en) * 2007-09-07 2009-03-26 Cisthera Incorporated Humanized PAI-1 Antibodies
WO2011139973A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Methods of inhibiting fibrosis using anti-pai-1 antibodies
CN105705520A (zh) * 2013-08-13 2016-06-22 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
DK319685A (da) * 1985-07-12 1987-01-13 Fonden Til Fremme Af Eksperime Monoklonale antistoffer, fremgangsmaade til frembringelse af antistofferne, hybridomaceller, der producerer antistofferne, og anvendelse af antistofferne
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JP2750732B2 (ja) * 1988-04-04 1998-05-13 帝人株式会社 ヒトプラスミノーゲンアクティベーターインヒビター・１−ヒト組織プラスミノーゲンアクティベーター複合体の免疫学的測定方法
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0521985B1 (en) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DK85193D0 (da) * 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
JPH1014592A (ja) * 1996-07-04 1998-01-20 Tanabe Seiyaku Co Ltd ラットｐａｉ−１に対するモノクローナル抗体
ES2300113T3 (es) 1996-08-02 2008-06-01 Bristol-Myers Squibb Company Un procedimiento para inhibir toxicidad inducida por inmunoglobulinas que resulta del uso de inmunoglobulinas en terapia y diagnostico in vivo.
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
WO2002034776A2 (en) 2000-10-26 2002-05-02 K.U.Leuven Research And Development Epitopes of pai-1
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2478011C (en) 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
CN1668312A (zh) * 2002-05-13 2005-09-14 洛杉矶儿童医院 疤痕疙瘩和其它的皮肤或内部的创伤或损伤中异常疤痕形成的处理和抑制
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
EP2502935B1 (en) 2003-08-22 2017-03-29 Biogen MA Inc. Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
JP2008505174A (ja) 2004-07-15 2008-02-21 ゼンコー・インコーポレイテッド 最適化Ｆｃ変異体
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
US20090202524A1 (en) 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
PT2195023T (pt) 2007-08-29 2018-06-08 Sanofi Sa Anticorpos anti-cxcr5 humanizados, seus derivados e suas utilizações
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US8410251B2 (en) * 2008-06-20 2013-04-02 National University Corporation Okayama University Antibody against calcified globule and use of the same
US20100254979A1 (en) * 2009-03-06 2010-10-07 Cisthera, Incorporated Humanized PAI-1 Antibodies and Uses Thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422245A (en) * 1985-07-12 1995-06-06 Fonden Til Fremme Af Eksperimental Cancerforskning Plasminogen activator inhibitor monoclonal antibodies, hybridomas, monoclonal antibody production and use of the antibodies for assay of the inhibitors
US20020086838A1 (en) * 2000-01-14 2002-07-04 Tanox, Inc. Use of antagonists of plasminogen activator inhibitor-1 (PAI-1) for the treatment of asthma and chronic obstructive pulmonary disease
US20030217371A1 (en) * 2002-02-19 2003-11-20 Vanderbilt University Therapeutic methods employing PAI-1 inhibitors and transgenic non-human animal for screening candidate PAI-1 inhibitors
US20090081239A1 (en) * 2007-09-07 2009-03-26 Cisthera Incorporated Humanized PAI-1 Antibodies
WO2011139973A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Methods of inhibiting fibrosis using anti-pai-1 antibodies
CN105705520A (zh) * 2013-08-13 2016-06-22 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REROLLE等: "Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis", KIDNEY INTERNATIONAL, vol. 58, no. 5, 1 December 2000 (2000-12-01), pages 1841 - 1850, XP002415871, DOI: 10.1111/j.1523-1755.2000.00355.x *
周子鑫等: "t-PA、PAI-1在慢性肾小球肾炎中的表达及意义", 福建医药杂志, vol. 27, no. 6, 23 February 2006 (2006-02-23), pages 163 - 164 *

Also Published As

Publication number Publication date
CN105705520B (zh) 2020-09-25
MX2016001851A (es) 2016-05-16
JP6907380B2 (ja) 2021-07-21
MX2019008803A (es) 2019-09-16
US20180155444A1 (en) 2018-06-07
BR112016002753A2 (pt) 2017-11-21
JP2021155440A (ja) 2021-10-07
HK1221725A1 (zh) 2017-06-09
JP7764565B2 (ja) 2025-11-05
EA033403B1 (ru) 2019-10-31
CR20160117A (es) 2016-05-20
KR20160035077A (ko) 2016-03-30
JP2016529255A (ja) 2016-09-23
JP2023055852A (ja) 2023-04-18
UA118267C2 (uk) 2018-12-26
DOP2016000042A (es) 2016-04-04
JP6696899B2 (ja) 2020-05-20
PH12016500239A1 (en) 2016-05-16
JP2020125333A (ja) 2020-08-20
ES2770507T3 (es) 2020-07-01
US20190359729A1 (en) 2019-11-28
CL2016000324A1 (es) 2016-10-21
TN2016000048A1 (en) 2017-07-05
US20160200831A1 (en) 2016-07-14
CR20190319A (es) 2019-08-29
SG10201710013RA (en) 2018-01-30
PE20160244A1 (es) 2016-05-10
JP7223069B2 (ja) 2023-02-15
JP7568756B2 (ja) 2024-10-16
JP2025011161A (ja) 2025-01-23
EA201690377A1 (ru) 2016-06-30
US20230015181A1 (en) 2023-01-19
CN105705520A (zh) 2016-06-22
US9845363B2 (en) 2017-12-19

Similar Documents

Publication Publication Date Title
JP7764565B2 (ja) プラスミノーゲン活性化因子阻害剤－１（ｐａｉ－１）に対する抗体及びその使用
TWI592426B (zh) 胞漿素原活化素抑制劑－１（ｐａｉ－１）之抗體及其用途
KR102035882B1 (ko) 브라디키닌 b1 수용체 리간드에 대한 항체
HK1254947A1 (zh) 針對組織因子途徑抑制劑(tfpi)的優化的單克隆抗體
WO2012109285A2 (en) Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
AU2012214531A1 (en) Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use
JP2020099329A (ja) 抗ＨｔｒＡ１抗体及びその使用方法
CN111683965B (zh) 用于治疗骨折或骨缺损的gremlin-1抑制剂
HK40044528A (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
HK40023283A (en) Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
AU2016269554B2 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
HK40091539A (zh) 新的抗a2ap抗体及其用途
HK40018254A (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HK40037006A (en) Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect
HK40037006B (zh) 用於治疗骨折或骨缺损的gremlin-1抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40044528

Country of ref document: HK